Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) — Market Cap & Net Worth
Market Cap & Net Worth: Avalyn Pharma Inc. Common Stock (AVLN)
Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) has a market capitalization of $1.14 Billion ($1.14 Billion) as of May 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8580 globally and #2365 in its home market, demonstrating a -7.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avalyn Pharma Inc. Common Stock's stock price $28.41 by its total outstanding shares 41812047 (41.81 Million). Analyse how efficiently does Avalyn Pharma Inc. Common Stock generate cash to see how efficiently the company converts income to cash.
Avalyn Pharma Inc. Common Stock Market Cap History: 2026 to 2026
Avalyn Pharma Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.19 Billion to $1.19 Billion (0.00% CAGR).
Avalyn Pharma Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avalyn Pharma Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AVLN by Market Capitalization
Companies near Avalyn Pharma Inc. Common Stock in the global market cap rankings as of May 23, 2026.
Key companies related to Avalyn Pharma Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Avalyn Pharma Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Avalyn Pharma Inc. Common Stock's market cap moved from $1.19 Billion to $ 1.19 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.19 Billion | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of Avalyn Pharma Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more